Ensuring Medicine Supply Chain Resilience in Disasters: A Grounded Approach

By Staff Writer

August 18, 2023

Medicines and medical supplies are crucial in maintaining human health, particularly during disasters when their availability can be significantly impacted. This is especially true in developing countries, where the provision of these supplies is a critical priority. Disruptions in the medication supply chain can lead to serious consequences, from loss of revenue for companies to endangering lives. This article explores the causes, strategies, and consequences of such disruptions, using the Kermanshah, Iran earthquake in 2018 as a case study.

The study found that “waste of time and resources” was the most critical issue in the medication supply chain during disasters. Strategies to reduce this waste, such as efficient resource management and the use of an up-to-date information system, were identified as crucial in increasing supply chain resilience. Sociocultural factors, as well as the need for planning and designing an appropriate disaster management structure, were also highlighted as significant underlying factors affecting the prevention of resource waste.

The study emphasised the need for effective disaster management planning, and the importance of a comprehensive needs assessment based on the region’s characteristics, including its epidemiological needs, disease, and demographic characteristics. Paying attention to sociocultural factors and developing localised policies under cultural conditions, social needs, and the level of acceptance and cooperation of the people of each region were also recommended.


To achieve resilience in the medication supply chain during disasters, health policymakers must seek applied and context-based strategies for decreasing the waste of resources. These strategies should include sociocultural interventions, preparing necessary information infrastructures, and improving coordination among the stewards and the community during disasters. Improving logistic operations and monitoring the coordination between the local need assessments and the pharmaceutical supplies and procurement are also essential steps in improving medication supply chain resilience. 

Reference url

Recent Posts

oral GLP-1 medication
    

Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron Succeeds in Phase 3

🌟 Ready for a breakthrough in diabetes management?

Eli Lilly’s oral GLP-1 medication, orforglipron, has completed a successful Phase 3 trial, showing remarkable efficacy in lowering A1C levels and promoting substantial weight loss. As the first oral small molecule GLP-1 receptor agonist, it offers a promising alternative to conventional injectable treatments, potentially improving patient adherence and access.

Dive into the details of this exciting development and what it means for the future of diabetes care!

#SyenzaNews #HealthTech #Innovation #Pharmaceuticals

pediatric thyroid cancer risk
    

Environmental Exposures and Pediatric Thyroid Cancer Risk: Key Findings from a California Study

🌟 Are we overlooking environmental risks in pediatric cancer?

Recent research highlights a troubling link between perinatal exposure to PM2.5 and outdoor artificial light and the increased risk of pediatric thyroid cancer. This pivotal study sheds light on how environmental factors play a critical role in childhood health, particularly among vulnerable populations.

Dive into this important discussion on how addressing these environmental exposures may reduce pediatric thyroid cancer and improve health outcomes for future generations.

#SyenzaNews #EnvironmentalHealth #HealthPolicy #Innovation

capivasertib cost-effectiveness
      

Capivasertib Cost-Effectiveness in Advanced Breast Cancer

💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?

A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.

Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.

#SyenzaNews #HealthEconomics #costeffectiveness #oncology

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.